Home Services In Country Services

news010

FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access

Cell Therapeutics (CTI) has decided to pursue an expanded access program for its non-Hodgkin’s lymphoma drug Pixuvri, while conducting an additional trial needed for approval. CTI plans to request a meeting with the FDA to discuss the expanded access program and design of the follow-on study. The company said it received a complete response letter from the agency citing concerns with trial data raised at a meeting of the Oncologic Drugs Advisory Committee last month.
Drug Industry Daily

News & Events

  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>